B
MRSN

Braidwell’s Mersana Therapeutics MRSN Stock Holding History

Braidwell’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-134,232
Closed -$13.8M – 88
2023
Q1 		$13.8M Buy
134,232
+59,724
+80% +$8.38M 0.45% 62
2022
Q4 		$10.9M Buy
+74,508
New +$12.6M 0.37% 69

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Braidwell's MRSN Position: Q2 2023 in Review

Braidwell sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 134,232 shares — an estimated $13.8M sold.

Braidwell first reported a position in MRSN in Q4 2022 and held it in 2 quarters. The position peaked at $13.8M in Q1 2023. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Braidwell reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Braidwell sold 134,232 Mersana Therapeutics shares in Q2 2023, an estimated $13.8M.
  • Braidwell first reported a position in Mersana Therapeutics in Q4 2022 and held it in 2 quarters.
  • Braidwell's Mersana Therapeutics position peaked at $13.8M in Q1 2023.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.